

Yasuhiro Fujiwara

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2983752/yasuhiro-fujiwara-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

223
papers

6,289
citations

38
h-index

71
g-index

225
ext. papers

7,180
ext. citations

5.1
avg, IF

5.11
L-index

#	Paper	IF	Citations
223	PMDAR efforts to promote medical innovation in the coronavirus pandemic. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2022 , 95, 1-SL04	0	0
222	Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers. <i>BMC Cancer</i> , 2021 , 21, 1131	4.8	0
221	Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers.. <i>Frontiers in Oncology</i> , 2021 , 11, 732525	5.5	1
220	Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. <i>Clinical and Translational Science</i> , 2021 , 14, 1015-1025	4.9	0
219	No-fault compensation schemes for COVID-19 medical products. <i>Lancet, The</i> , 2021 , 397, 1707-1708	40	1
218	Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. <i>JCO Oncology Practice</i> , 2021 , 17, e416-e425	2.3	5
217	Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1182-1185	6.1	0
216	Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. <i>Oncology</i> , 2020 , 98, 699-705	3.6	2
215	Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. <i>Case Reports in Oncological Medicine</i> , 2020 , 2020, 2518383	0.9	3
214	Toward global standardization of conducting fair investigations of allegations of research misconduct. <i>Accountability in Research</i> , 2020 , 27, 327-346	1.9	3
213	MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 596-605	6.1	6
212	Future development of artificial organs related with cutting edge emerging technology and their regulatory assessment: PMDAR perspective. <i>Journal of Artificial Organs</i> , 2020 , 23, 203-206	1.8	2
211	Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. <i>Drug Safety</i> , 2020 , 43, 233-242	5.1	6
210	MiR-1285-5p/TMEM194A axis affects cell proliferation in breast cancer. <i>Cancer Science</i> , 2020 , 111, 395-405	4.5	13
209	Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer. <i>Oncology Letters</i> , 2020 , 20, 336	2.6	1
208	HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix. <i>Oncology Letters</i> , 2020 , 20, 38	2.6	0
207	Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 558-566	2.2	14

206	Rare cancers in Japan: definition, clinical features and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 970-975	2.8	1
205	Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging. <i>Scientific Reports</i> , 2020 , 10, 15535	4.9	3
204	BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 323-329	4.4	2
203	Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. <i>BMC Cancer</i> , 2020 , 20, 325	4.8	6
202	A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. <i>European Journal of Cancer</i> , 2019 , 109, 84-91	7.5	12
201	Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on F-fluorodeoxyglucose positron emission tomography/computed tomography. <i>Medical Oncology</i> , 2019 , 36, 58	3.7	4
200	Expectations of and recommendations for a cancer survivorship guideline in Japan: a literature review of guidelines for cancer survivorship. <i>Japanese Journal of Clinical Oncology</i> , 2019 , 49, 812-822	2.8	9
199	Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development. <i>Drug Metabolism and Pharmacokinetics</i> , 2019 , 34, 209-216	2.2	20
198	Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. <i>Cancer Science</i> , 2019 , 110, 1480-1490	6.9	117
197	A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 803-809	6.1	2
196	Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. <i>Breast Cancer</i> , 2019 , 26, 492-498	3.4	14
195	Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study. <i>Breast Cancer</i> , 2019 , 26, 39-46	3.4	0
194	Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. <i>Translational Oncology</i> , 2019 , 12, 1386-1394	4.9	5
193	Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. <i>Targeted Oncology</i> , 2019 , 14, 647-656	5	6
192	Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 491-492	6.1	6
191	The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site. <i>Internal Medicine</i> , 2019 , 58, 1423-1428	1.1	2
190	A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. <i>British Journal of Cancer</i> , 2019 , 120, 475-480	8.7	58
189	Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data. <i>Oncologist</i> , 2019 , 24, 266-272	5.7	2

188	Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing. <i>Lung Cancer</i> , 2019 , 128, 20-25	5.9	1
187	Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40-44 years. <i>Breast Cancer</i> , 2019 , 26, 386-396	3.4	6
186	Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor. <i>Oncology</i> , 2018 , 94, 340-344	3.6	14
185	Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. <i>Therapeutic Innovation and Regulatory Science</i> , 2018 , 52, 334-338	1.2	3
184	Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. <i>Supportive Care in Cancer</i> , 2018 , 26, 2161-2166	3.9	24
183	Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. <i>Investigational New Drugs</i> , 2018 , 36, 151-155	4.3	3
182	Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionization mass spectrometry imaging: a pilot study. <i>British Journal of Pharmacology</i> , 2018 , 175, 29-37	8.6	12
181	PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. <i>Cancer Science</i> , 2018 , 109, 2558-2566	6.9	23
180	Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site. <i>BMC Cancer</i> , 2018 , 18, 176	4.8	3
179	Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 275-283	3.5	1
178	MASTER KEY project: A basket/umbrella trial for rare cancers in Japan.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS2598-TPS2598	2.2	2
177	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. <i>Oncotarget</i> , 2018 , 9, 18540-18547	2.3	9
176	A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin. <i>Anti-Cancer Drugs</i> , 2018 , 29, 97-101	2.4	6
175	TERT promoter hotspot mutations in breast cancer. <i>Breast Cancer</i> , 2018 , 25, 292-296	3.4	22
174	Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. <i>Cancer Science</i> , 2018 , 109, 207-214	6.9	7
173	Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 1179-1186	3.5	25
172	Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. <i>Cancer Science</i> , 2017 , 108, 1520-1529	6.9	13
171	The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 1850-1855	3.5	4

170	Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging. <i>Scientific Reports</i> , 2017 , 7, 12622	4.9	16
169	Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. <i>Lancet Oncology</i> , 2017 , 18, 1512-1522	21.7	195
168	Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study. <i>BMC Cancer</i> , 2017 , 17, 819	4.8	10
167	Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>Cancer Science</i> , 2017 , 108, 987-994	6.9	13
166	Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy. <i>Internal Medicine</i> , 2017 , 56, 2879-2882	1.1	3
165	Visualization of HER2-specific breast cancer intratumoral heterogeneity using Cu-DOTA-trastuzumab PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 2146-2147	8.8	12
164	Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. <i>ESMO Open</i> , 2017 , 2, e000150	6	73
163	Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 127-134	3.5	10
162	The Incidence and Severity of Paclitaxel-induced Peripheral Neuropathy in Patients with Ovarian Cancer: a Retrospective Study. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2017 , 43, 252-259	0.1	
161	Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab. <i>Breast Cancer</i> , 2016 , 23, 624-32	3.4	7
160	Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 745-52	3.5	8
159	Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. <i>Molecular Cancer</i> , 2016 , 15, 73	42.1	32
158	The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study. <i>Breast Cancer</i> , 2016 , 23, 797-806	3.4	1
157	Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. <i>Supportive Care in Cancer</i> , 2016 , 24, 447-455	3.9	114
156	Molecular imaging using PET for breast cancer. <i>Breast Cancer</i> , 2016 , 23, 24-32	3.4	19
155	III. Advanced Medical Care B and Patient-proposed Health Services. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2016 , 105, 2336-2345	0	2
154	Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging. <i>Scientific Reports</i> , 2016 , 6, 23749	4.9	32
153	Drug induced interstitial lung disease in oncology phase II trials. <i>Cancer Science</i> , 2016 , 107, 1830-1836	6.9	7

152	Evolution of frameworks for expediting access to new drugs in Japan. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 293-4	64.1	25
151	Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents. <i>Oncologist</i> , 2016 , 21, 508-13	5.7	19
150	Novel combination of serum microRNA for detecting breast cancer in the early stage. <i>Cancer Science</i> , 2016 , 107, 326-34	6.9	197
149	A phase I study of farletuzumab, a humanized anti-folate receptor I monoclonal antibody, in patients with solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 332-40	4.3	22
148	Japanese universal health care faces a crisis in cancer treatment. <i>Lancet Oncology, The</i> , 2015 , 16, 251-2	21.7	15
147	Back with a vengeance: microvascular tumor embolism. <i>American Journal of Medicine</i> , 2015 , 128, 834-6	2.4	1
146	Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015 , 45, 12-8	2.8	12
145	(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. <i>EJNMMI Research</i> , 2015 , 5, 8	3.6	62
144	Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. <i>Breast Cancer</i> , 2015 , 22, 141-52	3.4	31
143	Perception and needs of reproductive specialists with regard to fertility preservation of young breast cancer patients. <i>International Journal of Clinical Oncology</i> , 2015 , 20, 82-9	4.2	11
142	The expression and clinical significance of ribophorin II (RPN2) in human breast cancer. <i>Pathology International</i> , 2015 , 65, 301-8	1.8	17
141	Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 401-9	4.4	50
140	Nucleostemin expression in invasive breast cancer. <i>BMC Cancer</i> , 2014 , 14, 215	4.8	17
139	A descriptive analysis of post-chemotherapy development of interstitial lung disease using spontaneous reporting data in Japan. <i>Current Drug Safety</i> , 2014 , 9, 220-6	1.4	1
138	Physicians' knowledge, attitude, and behavior regarding fertility issues for young breast cancer patients: a national survey for breast care specialists. <i>Breast Cancer</i> , 2013 , 20, 230-40	3.4	55
137	Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer. <i>Breast Cancer</i> , 2013 , 20, 145-51	3.4	16
136	A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1369-74	3.5	8
135	Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: a randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy. <i>Breast</i> , 2013 , 22, 263-7	3.6	20

134	A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2013 , 18, 621-8	4.2	19
133	A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. <i>International Journal of Clinical Oncology</i> , 2013 , 18, 590-7	4.2	7
132	Impact of recent parity on histopathological tumor features and breast cancer outcome in premenopausal Japanese women. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 941-50	4.4	19
131	Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. <i>International Journal of Clinical Oncology</i> , 2013 , 18, 132-8	4.2	70
130	⁶⁴ Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1869-75	8.9	178
129	Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. <i>Molecular and Clinical Oncology</i> , 2013 , 1, 995-1001	16.1	9
128	Quantitative assessment of appearance changes and related distress in cancer patients. <i>Psycho-Oncology</i> , 2013 , 22, 2140-7	3.9	39
127	The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. <i>Breast</i> , 2012 , 21, 289-95	3.6	69
126	A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2012 , 125, 307-11	4.9	25
125	Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen. <i>Cancer Science</i> , 2012 , 103, 491-6	6.9	2
124	Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 457-65	3.5	30
123	The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 319-24	2.8	6
122	Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. <i>Cancer Science</i> , 2012 , 103, 1665-71	6.9	78
121	Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 391-7	3.5	9
120	Immunohistochemical profile for unknown primary adenocarcinoma. <i>PLoS ONE</i> , 2012 , 7, e31181	3.7	19
119	Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 1249-57	4.9	10
118	Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 793-805	4.4	205
117	Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer. <i>Clinical Breast Cancer</i> , 2012 , 12, 49-56	3	7

116	Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. <i>Clinical Cancer Research</i> , 2012 , 18, 4841-9	12.9	102
115	Hematologic safety of breast cancer chemotherapies in patients with hepatitis B or C virus infection. <i>Oncology</i> , 2012 , 82, 228-33	3.6	3
114	Primary yolk sac tumor of the omentum: a case report and literature review. <i>Case Reports in Oncology</i> , 2012 , 5, 671-5	1	7
113	Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. <i>Biological and Pharmaceutical Bulletin</i> , 2012 , 35, 717-24	2.3	26
112	Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal. <i>PLoS ONE</i> , 2012 , 7, e44393	3.7	2
111	Breast Cancer Stem Cell: Translating to the Clinic 2012 , 249-257		1
110	Genomics, health care, and society. <i>New England Journal of Medicine</i> , 2011 , 365, 2339	59.2	4
109	Use of squamous cell carcinoma antigen as a biomarker of chemotherapy response in patients with metastatic cervical carcinoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011 , 159, 394-8	2.4	14
108	Atypical tumor-stromal fibroblasts in invasive ductal carcinomas of the breast treated with neoadjuvant therapy. <i>Human Pathology</i> , 2011 , 42, 998-1006	3.7	4
107	Do investigators show selection biases when enrolling patients in phase I oncology registration trials?. <i>Journal of Geriatric Oncology</i> , 2011 , 2, 25-30	3.6	1
106	Efficacy of taxane regimens in patients with metastatic angiosarcoma. <i>European Journal of Dermatology</i> , 2011 , 21, 539-45	0.8	20
105	Contrasting prognostic implications of platelet-derived growth factor receptor- β and vascular endothelial growth factor receptor-2 in patients with angiosarcoma. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2841-50	3.1	25
104	The notorious "drug lag" for oncology drugs in Japan. <i>Investigational New Drugs</i> , 2011 , 29, 706-12	4.3	33
103	First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 829-38	4.4	35
102	Second-line chemotherapy in patients with primary unknown cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 1185-91	4.9	3
101	Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 337-42	3.5	16
100	A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. <i>Medical Oncology</i> , 2011 , 28, 434-40	3.7	2
99	Prognostic factors in young Japanese women with breast cancer: prognostic value of age at diagnosis. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 180-9	2.8	13

98	De-identification procedure and sample quality of the post-clinical test samples at the bio-repository of the National Cancer Center Hospital (NCCH) in Tokyo. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 295-8	2.8	3
97	Reply to V. Fusco et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e523-e524	2.2	5
96	Reply to M.S. Apro. <i>Journal of Clinical Oncology</i> , 2011 , 29, e421-e423	2.2	1
95	Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010 , 6, 248-50	1.9	
94	Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5132-9 ^{2.2}		1150
93	Influence of suboptimal treatment in patients with mediastinal primary nonseminomatous germ cell tumors. <i>Oncology</i> , 2010 , 78, 34-9	3.6	1
92	Grading system for lymph vessel tumor emboli: significant outcome predictor for patients with invasive ductal carcinoma of the breast who received neoadjuvant therapy. <i>Modern Pathology</i> , 2010 , 23, 581-92	9.8	10
91	Do Patients With Platinum-Resistant Epithelial Ovarian Cancer Benefit From Second-line Chemotherapy?. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2010 , 3, 36-40		
90	Weekly Administration of Paclitaxel and Carboplatin in the Treatment of Advanced Ovarian or Peritoneal Cancers With Poor Performance Status. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2010 , 3, 47-51		0
89	Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. <i>Journal of Orthopaedic Science</i> , 2010 , 15, 654-60	1.6	21
88	Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 127-36	4.4	73
87	Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. <i>Cancer</i> , 2010 , 116, 302-8	6.4	90
86	Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. <i>Journal of Surgical Oncology</i> , 2010 , 101, 222-7	2.8	16
85	Feasibility and usefulness of the Distress Screening Program in Ambulatory Care in clinical oncology practice. <i>Psycho-Oncology</i> , 2010 , 19, 718-25	3.9	51
84	Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment. <i>Japanese Journal of Clinical Oncology</i> , 2009 , 39, 699-706	2.8	6
83	Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009 , 39, 484-90	2.8	12
82	Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial. <i>Japanese Journal of Clinical Oncology</i> , 2009 , 39, 443-8	2.8	11
81	Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. <i>Oncologist</i> , 2009 , 14, 752-9	5.7	34

80	Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma: case report. <i>Japanese Journal of Clinical Oncology</i> , 2009 , 39, 456-9	2.8	5
79	21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. <i>Breast</i> , 2009 , 18, 171-4	3.6	37
78	Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009 , 135, 551-7	4.9	14
77	Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , 2009 , 14, 48-52	4.2	29
76	Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. <i>Journal of Neuro-Oncology</i> , 2009 , 93, 205-12	4.8	107
75	Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 307-13	4.4	18
74	Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. <i>Medical Oncology</i> , 2009 , 26, 344-9	3.7	28
73	Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. <i>World Journal of Surgery</i> , 2009 , 33, 44-51	3.3	7
72	Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. <i>Journal of Proteome Research</i> , 2009 , 8, 457-62	5.6	20
71	Outpatient management of low-risk febrile patients on paclitaxel and carboplatin for ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2009 , 105, 261-2	4	
70	Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. <i>Cancer Science</i> , 2008 , 99, 1237-42	6.9	57
69	N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. <i>Cancer Science</i> , 2008 , 99, 1611-7	6.9	64
68	Therapy-related acute promyelocytic leukemia caused by hormonal therapy and radiation in a patient with recurrent breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 567-70	2.8	7
67	Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 214-21	3.8	9
66	Clinical efficacy of S-1 in pretreated metastatic breast cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 172-5	2.8	7
65	Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 777-85	2.8	29
64	Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma. <i>Oncology Reports</i> , 2008 ,	3.5	4
63	Immunohistochemical profiles of brain metastases from breast cancer. <i>Journal of Neuro-Oncology</i> , 2008 , 90, 223-8	4.8	29

62	Personalized systemic treatment for breast cancer patients: is it a reality?. <i>Breast Cancer</i> , 2008 , 15, 141-4	3.4	1
61	Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate. <i>International Journal of Clinical Oncology</i> , 2008 , 13, 555-8	4.2	5
60	Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008 , 134, 389-95	4.9	5
59	Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008 , 134, 1199-206	4.9	11
58	Development and validation of diagnostic prediction model for solitary pulmonary nodules. <i>Respirology</i> , 2007 , 12, 856-62	3.6	45
57	Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. <i>Breast</i> , 2007 , 16, 482-8	3.6	21
56	Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. <i>European Urology</i> , 2007 , 52, 1115-22	10.2	36
55	Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2007 , 103, 313-8	4.4	4
54	Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. <i>Medical Oncology</i> , 2007 , 24, 425-30	3.7	12
53	Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2007 , 37, 1-8	2.8	15
52	The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 100, 412-6	4.9	43
51	Effectiveness of MAID Therapy against Metastatic Malignant Phyllodes Tumors and Stromal Sarcoma of the Breast. <i>Breast Care</i> , 2006 , 1, 194-197	2.4	2
50	The next step to approaching central nervous system metastasis in HER-2-positive metastatic breast cancer patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006 , 2, 6-8	1.9	4
49	Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. <i>Pathology Research and Practice</i> , 2006 , 202, 705-12	3.4	33
48	Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2006 , 99, 9-17	4.4	118
47	Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006 , 132, 635-42	4.9	11
46	Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. <i>International Journal of Clinical Oncology</i> , 2006 , 11, 421-5	4.2	18
45	Re: Insulinlike growth factor 1 receptor: predictive factor in breast cancer patients treated with trastuzumab?. <i>Human Pathology</i> , 2005 , 36, 449-449	3.7	1

44	Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients. <i>Breast Journal</i> , 2005 , 11, 311-6	1.2	16
43	A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. <i>Cancer</i> , 2005 , 104, 1204-12	6.4	10
42	Translational studies for target-based drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 56 Suppl 1, 90-3	3.5	11
41	Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients. <i>International Journal of Clinical Oncology</i> , 2005 , 10, 272-5	4.2	2
40	Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005 , 89, 237-41	4.4	26
39	The Role of DNA-Microarray in Translational Cancer Research. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2005 , 3, 201-216		1
38	Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. <i>Human Pathology</i> , 2004 , 35, 1537-42	3.7	97
37	Issues in the investigator-initiated registration-directed clinical trials. <i>Drug Delivery System</i> , 2004 , 19, 453-460	0	
36	Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC). <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 42, 145-55	7	26
35	Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 48, 42-6	3.5	28
34	Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. <i>International Journal of Cancer</i> , 2000 , 86, 95-100	7.5	34
33	Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer. <i>Cancer Letters</i> , 2000 , 156, 93-9	9.9	27
32	Current status of oral anticancer drugs in Japan. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3362-5	2.2	11
31	Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer. <i>Japanese Journal of Cancer Research</i> , 1998 , 89, 855-61		9
30	ZK1, a novel Krüppel-type zinc finger gene, is induced following exposure to ionizing radiation and enhances apoptotic cell death on hematopoietic cells. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 249, 595-600	3.4	12
29	The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. <i>Japanese Journal of Cancer Research</i> , 1997 , 88, 1211-7		42
28	Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. <i>Japanese Journal of Cancer Research</i> , 1997 , 88, 218-23		64
27	Overcoming CPT-11 resistance by using a biscochlorine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. <i>International Journal of Cancer</i> , 1997 , 72, 295-300	7.5	9

26	No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. <i>Japanese Journal of Cancer Research</i> , 1996 , 87, 1280-7		33
25	Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer. <i>Japanese Journal of Cancer Research</i> , 1995 , 86, 490-500		7
24	High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. <i>Biomedical Applications</i> , 1995 , 670, 309-16		47
23	Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995 , 121, 729-38	4.9	23
22	Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. <i>Japanese Journal of Cancer Research</i> , 1994 , 85, 1240-6		46
21	Cis-diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung-cancer cells. <i>International Journal of Cancer</i> , 1993 , 55, 616-22	7.5	20
20	The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). <i>Japanese Journal of Cancer Research</i> , 1993 , 84, 83-92		38
19	Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 188, 571-7	3.4	93
18	In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 30, 417-22	3.5	9
17	Alteration of type II regulatory subunit of cAMP-dependent protein kinase in human cisplatin-resistant cells as a basis of collateral sensitivity to 8-chloro-cAMP. <i>Japanese Journal of Cancer Research</i> , 1992 , 83, 754-60		7
16	Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992 , 119, 28-34	4.9	20
15	Increased phosphorylation of nuclear phosphoproteins in human lung-cancer cells resistant to cis-diamminedichloroplatinum (II). <i>International Journal of Cancer</i> , 1992 , 50, 438-42	7.5	11
14	Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. <i>Japanese Journal of Cancer Research</i> , 1991 , 82, 747-51		31
13	Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-O-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multi-drug resistance. <i>International Journal of Cancer</i> , 1991 , 48, 931-7	7.5	16
12	Lack of correlation between interferon levels induced by polyribonucleotides and their antimetastatic effect. <i>Oncology</i> , 1990 , 47, 251-6	3.6	7
11	Determinants of drug response in a cisplatin-resistant human lung cancer cell line. <i>Japanese Journal of Cancer Research</i> , 1990 , 81, 527-35		65
10	Detection of proteins that recognize platinum-modified DNA using gel mobility shift assay. <i>Japanese Journal of Cancer Research</i> , 1990 , 81, 1210-3		7
9	Characterization of an etoposide-resistant human small-cell lung cancer cell line. <i>Cancer Chemotherapy and Pharmacology</i> , 1990 , 26, 313-7	3.5	56

8	Pharmacokinetics of (glycolate-0,0 0 -diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 1989 , 23, 243-6	3.5	75
7	Inhibition of colony formation of drug-resistant human tumor cell lines by combinations of interleukin-2-activated killer cells and antitumor drugs. <i>Japanese Journal of Cancer Research</i> , 1989 , 80, 265-70		6
6	Serial measurement of sister chromatid exchanges in the peripheral lymphocytes of patients with lung cancer receiving chemotherapy in relation to bone marrow toxicity. <i>Japanese Journal of Cancer Research</i> , 1989 , 80, 783-6		5
5	Clinical features and the result of treatment for brain metastases in advanced non-small cell lung cancer.. <i>Japanese Journal of Lung Cancer</i> , 1989 , 29, 649-655	0.1	
4	In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay. <i>Cancer Chemotherapy and Pharmacology</i> , 1988 , 22, 246-50	3.5	53
3	Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. <i>Japanese Journal of Cancer Research</i> , 1988 , 79, 301-4		69
2	In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay. <i>Investigational New Drugs</i> , 1987 , 5, 353-9	4.3	7
1	Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan). <i>Journal of Cancer Research and Clinical Oncology</i> , 1987 , 113, 563-6	4.9	21